D'Amato G, Oldani V, Donner C F
Division of Respiratory and Allergic Diseases, High Speciality Hospital A. Cardarelli, Naples, Italy.
Monaldi Arch Chest Dis. 2003 Jan-Mar;59(1):25-9.
The immunoglobulin E (IgE) antibody plays a central role in the allergic immune responses. The ability to reduce circulating IgE with a humanized monoclonal antibody (omalizumab) represents a new therapeutic approach for the treatment of IgE-mediated allergic diseases. The use of an anti-IgE antibody in the treatment of asthma was first suggested in preliminary studies in which omalizumab demonstrated efficacy in attenuating both the early- and late-phase bronchial responses to inhaled aeroallergens. Therapy with omalizumab has demonstrated both a significant beneficial effect on a number of measures and a favorable safety profile. It reduces the frequency of asthma exacerbations and the need for inhaled corticosteroids (ICSs), and improves asthma symptoms, lung function, and quality of life. The anti-IgE approach to asthma treatment has several potential advantages, such as the treatment of other concomitant atopic diseases (allergic conjunctivitis and rhinitis, atopic dermatitis, and food allergy) regardless of atopiC of allergic sensitization.
免疫球蛋白E（IgE）抗体在过敏性免疫反应中起核心作用。用人源化单克隆抗体（奥马珠单抗）降低循环IgE的能力代表了一种治疗IgE介导的过敏性疾病的新方法。在初步研究中首次提出使用抗IgE抗体治疗哮喘，其中奥马珠单抗在减轻对吸入性气传变应原的早期和晚期支气管反应方面显示出疗效。奥马珠单抗治疗已显示出对多种指标有显著有益效果且安全性良好。它降低了哮喘发作的频率以及对吸入性糖皮质激素（ICS）的需求，并改善了哮喘症状、肺功能和生活质量。抗IgE治疗哮喘的方法有几个潜在优势，例如治疗其他伴随的特应性疾病（过敏性结膜炎和鼻炎、特应性皮炎和食物过敏），而不论过敏致敏的特应性如何。
